Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NN 8209

Drug Profile

NN 8209

Alternative Names: Anti-C5aR-151; NN-8209; NNC 0151; NNC 0151-0000-0000

Latest Information Update: 05 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 30 Sep 2013 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Netherlands (Parenteral)
  • 30 Sep 2013 Discontinued - Phase-II for Rheumatoid arthritis in Denmark, Czech Republic, Poland, Romania, United Kingdom and Hungary (SC)
  • 11 Feb 2013 Novo Nordisk completes a phase II trial in Rheumatoid arthritis in European Union (NCT01223911)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top